RxDoctor Payments Data

Michael Parry, MD

Infectious Disease · Stamford, CTNPI 1578535431

Payments from drug & device makers

What this record shows

This record is dominated by education: $100 of the $133 with a category attached, or 75.0%. Janssen Products, LP accounts for 75.0% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for infectious disease clinicians in CT, where the typical reported total is $181.

$133in general payments, 2019–2025

Across 2 payments — averaging $66.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Products, LP$100
  • Viiv Healthcare Company$33
$1,080,570in research payments, 2019–2025

Across 53 payments — averaging $20,388 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$1.1M

What the payments were for

  • Food & beverage$3325%
  • Education$10075%

General payments by program year

19
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Janssen Products, LP1$100
Viiv Healthcare Company1$33

How this compares

$133 in reported general payments places this provider in the 45th percentile of 159 infectious disease providers in Connecticut.

See all infectious disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$2,823
Medicare patients
17
Services billed
26

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GenvoyaElviteg/Cob/Emtri/Tenof Alafen24$103,000
Doxycycline Hyclate12$509

Paid to pharmacies, not to this prescriber.

Other infectious disease in Stamford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →